Program
roxadustat
Also written as “Roxadustat”, “FG-4592” and “ASP1517”.
Its studies are mostly in Anemia · Renal Insufficiency, Chronic · Kidney Failure, Chronic · Myelodysplastic Syndromes · Renal Insufficiency, led by 3 companies.
Drug pageRoxadustat: every studyAll 63 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Astellas Pharma | 221 open or running | phase 3since Jun 25, 2013 | Sep 15, 2009 | Oct 30, 2027phase 3 · NCT05970172 |
| Kyntra Bioits history only | 221 open or running | phase 4since Aug 8, 2019 | Sep 25, 2008 | Sep 2030phase 3 · NCT07722988 |
| AstraZenecaits history only | 30 open or running | phase 4since Dec 3, 2020 | Jun 24, 2014 | none ahead |
Also a collaborator on its studies: Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Astellas Pharma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 4 studies since Sep 15, 2009.
- Oct 15, 2013Phase 2 study in Kidney Failure, ChronicNCT01964196 · 107 enrolled · Japan
- Dec 20, 2013Phase 3 study in Renal Insufficiency, ChronicNCT02021318 · 616 enrolled · Austria, Belarus, Bulgaria and more
- Jun 9, 20143 phase 1 studiesNCT02161224, NCT02252731, NCT02161796
- Oct 28, 2014Phase 3 study in AnemiaNCT02278341 · 838 enrolled · Belgium, Bulgaria, Croatia and more
- Feb 3, 2016Phase 1 study in Healthy VolunteersNCT02693613 · 34 enrolled · Japan
- May 19, 20163 phase 3 studiesNCT02780141, NCT02779764, NCT02780726
- Jun 16, 2016Phase 1 study in Healthy SubjectsNCT02805374 · 16 enrolled · Japan
- Oct 31, 2016Phase 3 study in Hemodialysis Chronic Kidney Disease Patients With AnemiaNCT02952092 · 303 enrolled · Japan
- Oct 31, 2016Phase 1 study in Healthy SubjectsNCT02952040 · 18 enrolled · Japan
- Nov 11, 2016Phase 1 study in Renal InsufficiencyNCT02965040 · 34 enrolled · Germany, United Kingdom
- Nov 13, 2016Phase 3 study in Renal Insufficiency, ChronicNCT02964936 · 100 enrolled · Japan
- Dec 8, 2016Phase 3 study in Renal Insufficiency, ChronicNCT02988973 · 334 enrolled · Japan
- May 21, 2019Phase 1 study in Healthy Adult SubjectsNCT03960489 · 24 enrolled · Germany
- Jul 25, 2023Phase 3 study in Renal Insufficiency, ChronicNCT05970172 · 98 enrolled · Belgium, Croatia, Denmark and more
Ahead
- Oct 30, 2027Primary completion: phase 3 study in Renal Insufficiency, ChronicNCT05970172
TargetBeta
“Hypoxia-inducible factor prolyl hydroxylase inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| daprodustatrule | GlaxoSmithKline | phase 3 | 33 |
Studies
All 22 Astellas Pharma leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05970172Renal Insufficiency, Chronic · Belgium, Croatia, Denmark and more | 3 | Active, not recruiting | Oct 30, 2027 | 98 |
| NCT03960489Healthy Adult Subjects · Germany | 1 | Completed | Oct 14, 2019 | 24 |
| NCT02988973Renal Insufficiency, Chronic · Japan | 3 | Completed | Sep 13, 2019 | 334 |
| NCT02964936Renal Insufficiency, Chronic · Japan | 3 | Completed | Aug 15, 2018 | 100 |
| NCT02965040Renal Insufficiency · Germany, United Kingdom | 1 | Completed | Dec 4, 2017 | 34 |
| NCT02952092Hemodialysis Chronic Kidney Disease Patients With Anemia · Japan | 3 | Completed | Mar 13, 2018 | 303 |
| NCT02952040Healthy Subjects · Japan | 1 | Completed | Dec 2016 | 18 |
| NCT02805374Healthy Subjects · Japan | 1 | Completed | Aug 2016 | 16 |
| NCT02780726Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia · Japan | 3 | Completed | Aug 2, 2017 | 56 |
| NCT02780141ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia · Japan | 3 | Completed | Dec 12, 2017 | 75 |
| NCT02779764Hemodialysis Patients With Renal Anemia · Japan | 3 | Completed | May 16, 2017 | 164 |
| NCT02693613Healthy Volunteers · Japan | 1 | Completed | Apr 2016 | 34 |
| NCT02278341Anemia · Belgium, Bulgaria, Croatia and more | 3 | Completed | Jun 8, 2017 | 838 |
| NCT02252731Pharmacokinetics of FG-4592 · Germany | 1 | Completed | Nov 2013 | 22 |
| NCT02161796PK for FG-4592 · Germany | 1 | Completed | Dec 2013 | 48 |
| NCT02161224Hepatic Insufficiency · Bulgaria | 1 | Completed | Dec 2013 | 16 |
| NCT02021318Renal Insufficiency, Chronic · Austria, Belarus, Bulgaria and more | 3 | Completed | Mar 23, 2018 | 616 |
| NCT01964196Kidney Failure, Chronic · Japan | 2 | Completed | Jul 6, 2015 | 107 |
| NCT01888445Kidney Failure, Chronic · Japan | 2 | Completed | Sep 15, 2014 | 130 |
| NCT01887600Anemia · Belarus, Belgium, Bulgaria and more | 3 | Completed | Nov 1, 2017 | 594 |
| NCT01083888Anemia · Japan | 1 | Completed | Jun 7, 2010 | 12 |
| NCT00978198Healthy Volunteers · Japan | 1 | Completed | Jun 2010 | 100 |
How it is read
Names in the registry
- “Roxadustat”, 25 entries
- “FG-4592”, 9 entries
- “roxadustat”, 8 entries
- “ASP1517”, 5 entries
Conditions, from the studies’ own filings
- Anemia, 25 studies
- Renal Insufficiency, Chronic, 7 studies
- Kidney Failure, Chronic, 4 studies
- Myelodysplastic Syndromes, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.